| Q37023585 | A delicate balance: Iron metabolism and diseases of the brain. |
| Q37258755 | A low-molecular-weight ferroxidase is increased in the CSF of sCJD cases: CSF ferroxidase and transferrin as diagnostic biomarkers for sCJD. |
| Q34658144 | A novel transferrin/TfR2-mediated mitochondrial iron transport system is disrupted in Parkinson's disease |
| Q49455279 | A panel of clinical and neuropathological features of cerebrovascular disease through the novel neuroimaging methods. |
| Q28830946 | A synopsis on the role of tyrosine hydroxylase in Parkinson's disease |
| Q39722408 | Allelic imbalance of expression and epigenetic regulation within the alpha-synuclein wild-type and p.Ala53Thr alleles in Parkinson disease. |
| Q41115824 | Alpha-Synuclein Oligomers Interact with Metal Ions to Induce Oxidative Stress and Neuronal Death in Parkinson's Disease |
| Q39670506 | Alpha-synuclein aggregation is involved in the toxicity induced by ferric iron to SK-N-SH neuroblastoma cells |
| Q27024824 | Alzheimer's disease therapeutics targeted to the control of amyloid precursor protein translation: maintenance of brain iron homeostasis |
| Q37376532 | Amyloid precursor protein and alpha synuclein translation, implications for iron and inflammation in neurodegenerative diseases |
| Q36914433 | An iron responsive element-like stem-loop regulates alpha-hemoglobin-stabilizing protein mRNA. |
| Q37729558 | Blood Transcriptomic Meta-analysis Identifies Dysregulation of Hemoglobin and Iron Metabolism in Parkinson' Disease |
| Q38796693 | Brain Iron Metabolism Dysfunction in Parkinson's Disease. |
| Q37605018 | Brain iron homeostasis: from molecular mechanisms to clinical significance and therapeutic opportunities |
| Q36713371 | Cellular strategies for regulating functional and nonfunctional protein aggregation |
| Q36855866 | Constitutive translation of human α-synuclein is mediated by the 5'-untranslated region |
| Q39700323 | Dose- and time-dependent alpha-synuclein aggregation induced by ferric iron in SK-N-SH cells |
| Q36825286 | GATA transcription factors directly regulate the Parkinson's disease-linked gene alpha-synuclein |
| Q36815145 | Genetics of iron regulation and the possible role of iron in Parkinson's disease |
| Q48162038 | Increased iron levels correlate with the selective nigral dopaminergic neuron degeneration in Parkinson's disease |
| Q37577611 | Interaction between alpha-synuclein and metal ions, still looking for a role in the pathogenesis of Parkinson's disease. |
| Q38954686 | Interactions Between α-Synuclein and Tau Protein: Implications to Neurodegenerative Disorders |
| Q64076840 | Iron in Neurodegeneration - Cause or Consequence? |
| Q38186783 | Iron in neurodegenerative disorders of protein misfolding: a case of prion disorders and Parkinson's disease. |
| Q93000484 | Iron-mediated aggregation and toxicity in a novel neuronal cell culture model with inducible alpha-synuclein expression |
| Q33610411 | Iron-regulatory proteins: molecular biology and pathophysiological implications |
| Q59808733 | Kinetic Modeling of pH-Dependent Oxidation of Dopamine by Iron and Its Relevance to Parkinson's Disease |
| Q37968033 | M30, a brain permeable multitarget neurorestorative drug in post nigrostriatal dopamine neuron lesion of parkinsonism animal models |
| Q92028537 | Metal Chelation Therapy and Parkinson's Disease: A Critical Review on the Thermodynamics of Complex Formation between Relevant Metal Ions and Promising or Established Drugs |
| Q38921067 | Metals in Alzheimer's and Parkinson's Disease: Relevance to Dementia with Lewy Bodies |
| Q37750239 | Mitochondrial iron metabolism and its role in neurodegeneration. |
| Q37418049 | Neuroprotective molecular mechanisms of (-)-epigallocatechin-3-gallate: a reflective outcome of its antioxidant, iron chelating and neuritogenic properties |
| Q28535011 | Novel 5' untranslated region directed blockers of iron-regulatory protein-1 dependent amyloid precursor protein translation: implications for down syndrome and Alzheimer's disease |
| Q39179833 | Overview of iron metabolism in health and disease |
| Q39716036 | Oxidative stress partially contributes to iron-induced α-synuclein aggregation in SK-N-SH cells |
| Q89562082 | Parkinson's disease and iron |
| Q36810598 | Phenotypic screens for compounds that target the cellular pathologies underlying Parkinson's disease |
| Q30855088 | Physiological and pathological aspects of Abeta in iron homeostasis via 5'UTR in the APP mRNA and the therapeutic use of iron-chelators |
| Q37166339 | Physiological and pathological role of alpha-synuclein in Parkinson's disease through iron mediated oxidative stress; the role of a putative iron-responsive element |
| Q35868044 | RNA Structures as Mediators of Neurological Diseases and as Drug Targets |
| Q24610063 | Regulation of cellular iron metabolism |
| Q41467872 | Repositioning drugs for traumatic brain injury - N-acetyl cysteine and Phenserine |
| Q45927167 | Restoration of nigrostriatal dopamine neurons in post-MPTP treatment by the novel multifunctional brain-permeable iron chelator-monoamine oxidase inhibitor drug, M30. |
| Q37336898 | Simultaneous manipulation of multiple brain targets by green tea catechins: a potential neuroprotective strategy for Alzheimer and Parkinson diseases. |
| Q28818062 | Synthesis of the Alzheimer drug Posiphen into its primary metabolic products (+)-N1-norPosiphen, (+)-N8-norPosiphen and (+)-N1, N8-bisnorPosiphen, their inhibition of amyloid precursor protein, α-Synuclein synthesis, interleukin-1β release, and [...] |
| Q37299619 | Targeting the progression of Parkinson's disease. |
| Q51758684 | The Aging of Iron Man. |
| Q90206384 | The Association of Iron and the Pathologies of Parkinson's Diseases in MPTP/MPP+-Induced Neuronal Degeneration in Non-human Primates and in Cell Culture |
| Q61811707 | The Contribution of Iron to Protein Aggregation Disorders in the Central Nervous System |
| Q98189444 | The Iron Chelator Deferiprone Improves the Phenotype in a Mouse Model of Tauopathy |
| Q47835285 | The Relevance of Iron in the Pathogenesis of Multiple System Atrophy: A Viewpoint |
| Q33790013 | The alpha-synuclein 5'untranslated region targeted translation blockers: anti-alpha synuclein efficacy of cardiac glycosides and Posiphen |
| Q36012226 | The anticholinesterase phenserine and its enantiomer posiphen as 5'untranslated-region-directed translation blockers of the Parkinson's alpha synuclein expression |
| Q37725605 | The iron regulatory capability of the major protein participants in prevalent neurodegenerative disorders |
| Q92406693 | Translation of the intrinsically disordered protein α-synuclein is inhibited by a small molecule targeting its structured mRNA |
| Q58769184 | Untangling Tau and Iron: Exploring the Interaction Between Iron and Tau in Neurodegeneration |
| Q38892026 | α-Synuclein Over-Expression Induces Increased Iron Accumulation and Redistribution in Iron-Exposed Neurons. |